Kumaran G C, Jayson G C, Clamp A R
Department of Medical Oncology, Cancer Research UK, Manchester, UK.
Br J Cancer. 2009 Jan 13;100(1):1-7. doi: 10.1038/sj.bjc.6604767. Epub 2008 Nov 11.
Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
卵巢癌仍然是女性发病和死亡的主要原因。抗血管生成治疗已成为一种有前景的卵巢癌治疗策略。本文综述了支持在卵巢癌中使用抗血管生成治疗的理论依据、这类药物的临床研发情况以及这种治疗方式特有的毒性。
